CANNSUN MEDHEL Group of Companies More than a century - - PowerPoint PPT Presentation

F e b r u a r y 2 0 2 0

• CANNSUN-MEDHEL

More than a century

• f natures healthcare

INVESTOR PRESENTATION February 2020

CANNSUN MEDHEL

Group of Companies

S I N C E 1 9 1 8

F e b r u a r y 2 0 2 0

• CANNSUN-MEDHEL

THE INVESTMENT

2

Europe’s first pharmaceuticals, cosmetics & food for special medical purposes (FSMP) manufacturer with a vertically integrated cannabinoid division that includes EUGMP-certified manufacturing, production and extraction

CANNSUN MEDHEL

Established in 1918, one of the longest running pharmaceutical EUGMP-certified manufacturing and distribution companies in Western Europe.

F e b r u a r y 2 0 2 0

• CANNSUN-MEDHEL

WHY INVEST IN CANNSUN MEDHEL

ST STABLE, , HIGH GH MARGI GIN PHARMACEUTICAL MANUFA FACTURING G AND DIST STRIBUTION ON

3

EUGMP certified, pharmaceutical manufacturing and distribution facility serving Europe for over 100 years

05 04 01 02 03

Established distribution networks with a sales force of 30+ provide penetration in 21 countries globally Experienced management team with a track record of building pharmaceutical businesses Near term JV opportunities with large addressable populations and emerging botanicals and cannabinoid demand Pharmaceutical facility is scalable to address product demands in all components of production

F e b r u a r y 2 0 2 0

• CANNSUN-MEDHEL

4

Current markets (direct & through partnerships) Near-term JV opportunities GRE REECE Serbia Albania Thailand Malta Croatia Indonesia Uganda Cyprus Jordan Cambodia Vietnam Bulgaria Saudi Arabia Ethiopia Qatar Egypt Jamaica Lebanon South Africa Philippines Australia Iraq United Kingdom Austria Czech Republic Estonia Poland Kazakhstan Latvia New Zealand Germany Ghana Malaysia China Iraq Slovakia Lithuania Canada Russia Ukraine Kazakhstan Kyrgyzstan Georgia

ACCESS TO ESTABLISHED MARKETS

Key distribution hubs/in-country offices and staff GRE REECE Poland South Africa Thailand China Malaysia

F e b r u a r y 2 0 2 0

• CANNSUN-MEDHEL

___

EXISTING GLOBAL DISTRIBUTION

Greece

*Pending schedule 1 license. Potential near-term markets

Africa Asia Europe

Current Pharmaceutical/Cosmetics Future Botanical and Cannabinoid* Medhel Operations CR CREAT ATING SCAL CALABL ABLE JO JOINT VENTURES SAL ALES CH CHAN ANNELS

5 92% 8% Pharmaceutical/Cosmetics Future Botanical and Cannabinoid*

2020 Forecast

Revenue Distribution

F e b r u a r y 2 0 2 0

• CANNSUN-MEDHEL
• 70,

70,500 500 ft ft2 EU EUGMP certified pharmaceutical manufacturing

• Access to 100 wholesalers, 11,000 pharmacies,

35,000 doctors in over 21 countries in Europe, Asia & Africa

• Experienced management team in Greece to drive

manufacturing and distribution

• Obtaining Sch

Schedule I Lice cense in Q3 Q3 2020 - importation of THC and related products

• Undertaking a full mo

mode derni nization n and nd expa pans nsion n of existing facilities to add additional products and capacity

PHARMACEUTICALS

MEDHEL

Projected 2020 revenue of €31.0 MM

ESTABLISHED OPERATING COMMERCIAL COMPANY Current utilization < 5%

6

F e b r u a r y 2 0 2 0

• CANNSUN-MEDHEL

CURRENT PRODUCT OFFERINGS TOP REVENUE PRODUCTS TREATMENT SEGMENTS

R x & O T C P ha r m a c e ut i c a l s F ood f or S pe c i a l M e d i c a l P u r p os e s Cos m e t i c s M e d i c a l De vi c e s Fe r u m - Bl ood P r e s s ur e R e gul a t i on Om e p r a z o le – S t om a c h/ ul c e r A v e mar – F ood S uppl e m e nt Pa n th e n ol – S k i n Cr e a m P a i n m a na ge m e nt Ce n t r a l Ne r vou s S ys t e m Di a b e t e s In s om n i a S t r e s s O nc ol ogy

PRODUCT OFFERINGS & DEVELOPMENTS

7

F e b r u a r y 2 0 2 0

• CANNSUN-MEDHEL

8

5

NE NEW W PRODUCT OFFERING NGS & ADDITIONA NAL NA NATURAL ALTERNA NATIVES

Supplements – Wellness Botanical Medical Devices – Female Suppository CBD Cosmetics and Oral Consumption

PRODUCT OFFERINGS & DEVELOPMENTS

Prescriptions – Arthritis Medication

F e b r u a r y 2 0 2 0

• CANNSUN-MEDHEL

9

RESEARCH + DEVELOPMENT

We are focusing on R&D-driven growth, realizing collaborations with accredited academic and research centers:

• With support from the research/academic centers we anticipate developing

innovative products that would establish cutting edge therapeutic protocols for both cannabinoid and herbal medicines

• Clinical trials that support product development create niche molecules that

enable speed to market in EU, Africa & Asia

• Academy of Athens
• Pasteur Institute
• Stellenbosch University
• University of Athens Greece
• CRO Athens R&D
• Cape Peninsula University

9

1) Cardiovascular detection technology 2) Cystic Fibrosis pain treatment 3) Fatigue medication 4) Dialysis treatment technology Cu Current R&D Proj

• jects

5) Neuro pain management 6) Stress and anxiety treatment 7) Gynecology products 8) Cardiovascular/hypertension treatment

F e b r u a r y 2 0 2 0

• CANNSUN-MEDHEL

10

15

PROJECTED REVENUE PROFILE

Asset purchase October 2019, Cannsun Medhel Group sales and distribution initiated December 2019

15 30 45 60 75 90 105 120 135 150 2020 2021 2022 Revenue (€M)

THC Sales CBD Products Contract Mngt Services Selective Channel JV Sales Exports OTC/Cosmetics Food for Special Medical Needs Pharmaceuticals (Rx)

Projected Revenue: €31.0 Projected Revenue + JV: €52.0 €139.1 €101.3

F e b r u a r y 2 0 2 0

• CANNSUN-MEDHEL

NEAR TERM GROWTH + EXPANSION

Projected 2020 Growth

Pr Product ct Of Offering Ex Expa pans nsion Increasing product offering from 40 to 150 SKU’s globally Ca Cannsun Me Medhel Sou South Africa Marketing and distribution of pharmaceuticals, botanical and CBD product formulations Ca Cannsun Me Medhel As Asia Agreement to manufacture products for mass market sale Ca Cannsun Me Medhel Po Poland Expand distribution networks of cosmetics and medical devices

11

F e b r u a r y 2 0 2 0

• CANNSUN-MEDHEL

12

CAPITAL STRUCTURE

17

N U N U M B E R O F S H A R E S

Private Placement Closed January 2020: €4.0 million – €1.50 2,600,000 Shares Outstanding 27,515,739 Cu Current Private Placement: €8. €8.5 5 million

• n - $1.

$1.75/ 75/share 4, 4,900, 900,000 000 Stock Options - €1.50 2,800,000 Management Milestone shares - €1.50 1,200,000 Shares Outstanding, Fully Diluted 33,615,739

Pre-Raise Market Capitalization

€50 M

F e b r u a r y 2 0 2 0

• CANNSUN-MEDHEL

13

ASSET VALUATION

17

A s A s s e t s T o T o t a l C a p i t a l ( $ ) N e N e t P r e s e n t V a l u e 1 5 % ( $ ( $ ) I R I R R ( ( % )

Greece – Pharmaceutical Facility 33,700,000 86,800,000 100 South Africa – Cultivation/Extraction 8,000,000 29,900,000 80 Lesotho – Cultivation 3,000,000 14,300,000 96 Greece - Cultivation 7,000,000 17,200,000 66 TO TOTA TAL 51, 51,700, 700,000 000 148, 148,200, 200,000 000

Valuation models are based on a 6-year cash flow projection (2020-2025)

F e b r u a r y 2 0 2 0

• CANNSUN-MEDHEL

14

17

2017

Q3 Q3 2017 Molodhi est’d in Lesotho

TRACK-RECORD OF CREATING VALUE

Q1 Q1 2018 Cannsun South Africa est. 23 Hectare farm acquired Q2 Q2 2018 Agraleaf est. by Agraflora Organics in Northern Greece Q4 Q4 2018 Roughrider signs agreement to acquire Molodhi - License awarded in Q1 2019 Q2 Q2 2019 Cannsun Lesotho newly formed company is awarded license on 2.0 hectare site Q3 Q3 2019 Cannsun signs agreement to merge with Roughrider Q1 Q1 2020 60% of Cannsun Medhel Commercial acquisition Q4 Q4 2019 Cannsun Medhel signs agreement to acquire 100% Medhel Hellas Cannsun Medhel Group plc Ireland est. company begins process to redomicile to European Union Q1 Q1 2020 20%

• wnership in

Borealis Medhel Malaysia Q1 Q1/Q2 /Q2 2020 Formation of separate JV’s with China, Thailand & Poland. Commencing cosmetic sales in Africa. Amalgamation of Cannsun Medhel Group completion

1918: 1918: Medhel Greece was established – a pharmaceutical manufacture and distribution company

F e b r u a r y 2 0 2 0

• CANNSUN-MEDHEL

15

LEADERSHIP

19

BO BOARD OF DIRECTO CTORS

Chris Brocklesby CFO of Houwelings Group Rorisang Ntai South African based businessman Stephen Polakoff Lawyer with over 20 years M&A and Capital Markets experience Kiki Karagouni Professor at Pasteur Institute in plant-based medicine David Parry Co-founder of Cannsun Medhel Group Nikos Korbis Co-Founder and Chief Medical Officer

MA MANAGEME MENT

Nik Nikos

• s Kor
• rbis

is Chief Medical Officer Da Davi vid Parry Chief Executive Officer Ph Pholoso Malatji Co-Founder and Head of Africa Operations Gr Greg eg Bea Bealer er Director of Finance St Stephe phen n Po Polako koff General Counsel Aar Aaron

• n Katerench

chuk Chief Operating Officer Ar Artemios ios Ch Charalampakis Chief Commercial Officer

F e b r u a r y 2 0 2 0

• CANNSUN-MEDHEL

16

23

BU BUSINESS UNIT T LEADERS

Ca Cannsun South Africa ca Pholoso Malatji Ca Cannsun Les Lesotho Nicodema Ntai Leondios Caldis Ca Cannsun Greece ce Ag AgraL aLeaf af Manoli Kaldis Stavros Baxebanakis Ca Cannsun Me Medhe dhel Ph Phar arma ma Group Nikos Korbis Ca Cannsun Me Medhe dhel As Asia ia Bhunyanee Dethamart Ca Cannsun Me Medhe dhel Commerci cial Manos Angelakis Ca Cannsun Me Medhe dhel Africa ca Donaghue Woodman

LEADERSHIP

AD ADVISORY RY BOARD ARD

Peter Cummings Ex-Pharmaceutical retail executive and former Head of British Columbia Hothouse growers George Vourtis Post-production cultivation expert Eleni Chinou Professor of Pharmacognosy and Chemistry of Natural Products, University of Athens Chris Vourtis Cannabis industry expert Vassilis Dimou Corporate Finance

F e b r u a r y 2 0 2 0

• CANNSUN-MEDHEL

17

NEXT STEPS

1 5

• Increase product offerings of pharmaceuticals and global distribution networks
• Expansion of Greece manufacturing facility
• installation of additional equipment for incremental production and packaging capacity across all SKUs
• purchasing additional dossiers for prescription product expansion
• adding extraction equipment for CBD concentrate production
• Sales team expansion
• Leverage new JV agreements in Europe and Asia
• Commence cultivation operations
• Continue to advance R&D and clinical trials

F e b r u a r y 2 0 2 0

• CANNSUN-MEDHEL

18

USE OF PROCEEDS

Future capital raise and IPO planned for Q4 2020, size and structure is contingent on current expansion and execution plus additional pipeline of opportunities Capital raised on recent placements €7.0 MM, an additional €8.5 MM of capital required for facility expansion, product expansion and JV capital commitments

• Greece Facility Expansion: Equity financing €2.9 MM

(€18.9 MM through German Financial Institution at 1.6% interest)

• Operating working capital: €2.0MM
• Cannsun China Joint Venture: €2.0 MM
• South Africa distribution: €0.6 MM
• South Africa cultivation:€1.0 MM

F e b r u a r y 2 0 2 0

• CANNSUN-MEDHEL

w w w . c a n n s u n m e d h e l . c o m

30th Km ATHINON LAVRIOU MARKOPOULO, GREECE N.KORBIS@CANNSUN.COM +30 695 100 3705 DAVID@CANNSUN.COM +1 604 889 2188 +30 693 603 5933 3rd FLOOR CALDIS HOUSE 57A LONG STREET CAPE TOWN, 8001 REPUBLIC OF SOUTH AFRICA PHOLOSO@CANNSUN.COM +27 737 981 918 G.BEALER@CANNSUN.COM +1 780 970 3789

A F R I C A O F F I C E E U R O P E A N O F F I C E

19

F e b r u a r y 2 0 2 0

• CANNSUN-MEDHEL

APPENDICES

S I N C E 1 9 1 8

20

F e b r u a r y 2 0 2 0

• CANNSUN-MEDHEL

21

PHARMACEUTICAL PRODUCTS

5

EX EXTEN TENSIVE E PR PRODUCT T OFFER ERING OF PH PHARMA MACEU EUTI TICAL SOLUTI TIONS Prescription Drugs

• An

Anti-in inflam lammat atorie ies/Pain ain man anag agement: Nimesulide, Dicloduo

• Neu

eurologi gica cal/C /Cen entral Ner ervous s Syst stem em: Pregabalin, Rivastigmine, Risperidone, Donepezil, Quetiapine, Venlafaxine

• Onco

cology gy: Vitamin D3, Irinotecan, Capetitabine, Topotecan, Docatexel

• An

Anti-biotics cs: Macrolide, Levofloxacin

• Cardiovascu

scular: Simvastatin, Atorvastatin, Losartan + HCTZ, Rosuvastatin, Irbesartan

• Gas

Gastroin intestin inal al: Omeprazole, Pantoprazole

• Su

Supplements: Ferum, Calcifolin OTC Cosmetics

• An

Anti-itch ch: Med Calamine

• Ar

Arthritis & Pain: Med Cendium, Med Hot Ice

• Faci

cial Crea eam: Med Urea

• Bo

Body y Loti tion: Med Pathenol

• Ha

Hand Sanitizer zer: Med Care FSMPs and Devices

• Fe

Fema male Supposito tory: y: Lady Balance pH

• Radiation & Cancer

cer Trea eatmen ent: Rad-X, Rad-X Shampoo, Avenmar, Immax

• Gas

Gastroin intestin inal: al: Glutamine Complex, Adaptek, Nutrition Recover

F e b r u a r y 2 0 2 0

• CANNSUN-MEDHEL

22

6

S O S O U TH ER N A F R I C A

HEMP AND CANNABIS LICENSES

Cape Town Lesotho TOTAL Steady State Production: 36.0 million grams/year (2024) TOTAL Steady State Revenue: €72 million/year (€2.00/gram flower) TOTAL CAPEX: €25 million (debt financing level 50% - €4.0 MM government grant pending)

• Ca

Cape Tow

• wn

At Atlantis: 1 cultivation license pending, final inspection passed in December 2019. 23 hectare property with 3.0 hectare development planned for Phase 1. Tunnels currently constructed on site with flower processing facilities in place. First grow cycle planned for Q1 2020

• Le

Lesoth tho Al Alpine: 1 cultivation license awarded, 1.5 hectare Phase 1 development, construction currently underway Ma Maloti: 1 cultivation licence awarded, 2.0 hectare Phase 1 development, construction commencing H2 2020

• BBBEE complaint, increasing participation of South African labour in

economic activities

F e b r u a r y 2 0 2 0

• CANNSUN-MEDHEL

23

7

GR GREECE

HEMP & CANNABIS LICENSES

Thessaloniki

• Th

Thessaloniki ki: One THC/CBD cultivation licence awarded December 2019, 15 Hectare site in North Greece, 2.5 hectare greenhouse planned for phase 1, construction to commence 2020

• Flower used for extraction at Athens facility or for export

through Schedule 1 license

• One industrial hemp license awarded in conjunction with

cannabis license on property, provides flexibility in direction

• f operations

TOTAL Steady State Production: 22.5 million grams/year (2024) TOTAL Steady State Revenue: €39 million/year, €1.75/gram THC flower TOTAL CAPEX: €25 million (debt financing level 85%)

F e b r u a r y 2 0 2 0

• CANNSUN-MEDHEL

24

23

Pholoso Malatji Pholoso is currently responsible for the South African business operations for Cannsun Medhel Africa and Co-Founder of Cannsun SA. He has over 12 years experience in property valuation, agricultural market development for emerging farmers, consulting for government Agro-projects & land reform, bio energy and research. Pholoso has extensive experience as an Agricultural Economist (MSc. Agric), Property Valuer (BSc. Property Studies), Enterprise Development (Syracuse University) and accredited with the SA Council of Scientific Professions. Pholoso worked as a consultant to the FAO, Sub-Saharan Africa in Agricultural Development and Feasibility program for four years. David Parry Co-Founder of Cannsun South Africa and Chief Executive Officer of the Cannsun Medhel Group. David is also a Director of Propagation Services Canada one of the largest Cannabis facilities under glass in Canada, and Former Managing Director of Natures Hemp Ltd in Canada, a company developing food-based hemp products with the University of Manitoba and the Ontario Government. David has >20 years working with public and private companies in the agriculture, resource and technology sectors. He has an extensive network of contacts and relationships throughout MENA, Europe, the Former Soviet Union (FSU), Asia and Africa with significant experience in mergers and acquisitions.

LEADERSHIP BACKGROUND

F e b r u a r y 2 0 2 0

• CANNSUN-MEDHEL

25

23

LEADERSHIP BACKGROUND

Ro Rorisang Nt Ntai Rorisang has business interests in the petroleum and property development industries. He started his career at FNB Asset Management & Trust Services, after which he worked for Citadel, eventually as an investment analyst. He has an extensive network from which he can work with relevant specialists and experts to support current business interests or new project

• developments. He holds a BComm from (UNISA) University of South Africa and JSE RPE Exams from (SAIFM) South African

Institute of Financial Markets. St Stephen Po Polakoff Stephen has over 20 years of experience as general counsel, legal advisor, director and project manager at corporations, funds, law firms including Deutsche Bank (UFG), Integra Group, Clifford Chance, Damac Properties and several funds. He has gathered international experience having worked in New York, Moscow, Dubai and Geneva. His experience has been very diverse across sectors and territories including joint ventures and M&A, capital markets, debt and equity financing, infrastructure and funds. He has served on the boards of AIM, TSX and AIM-listed entities as well as several funds. Stephen graduated from Georgetown University Law School and is a member of the New York Bar. He speaks English and Russian and currently resides in Barcelona.

F e b r u a r y 2 0 2 0

• CANNSUN-MEDHEL

26

23

LEADERSHIP BACKGROUND

Ni Nickol

• las Ko

Korbi bis Nickolas has a Chemistry degree from the University of Athens and a PhD in Chemical Engineering from Imperial College in London. He has received several special training courses including Commodity Trading from Wharton School (Univ. Of Pennsylvania), GMP guidelines for the Pharmaceutical Industry from Leiden University and Design for Masking Flavors for the Pharmaceutical and Food industry from Hercules R&D center, amongst others. He is a certified GMP by EMA auditor and has done numerous valuations and appraisals for the industry. He has been working in Greece and abroad in both technical and managerial positions. He has been R&D manager in National Starch and Chemicals, Commercial Director in Biotrek, Vice President and Commercial Director in the Hellenic Register of Shipping, COO and IR Director in Alapis (the biggest Greek Pharma Co. at that time, raising more than €1.2B in deal roadshows), President and CEO for Provet (biggest animal healthcare company in the Balkans) among others. He has participated in more than 40 M&A’s and has set up pharmaceutical and other companies in more than 18 countries. He has also conducted several restructuring and financing projects creating a proven track record in these fields. Aa Aaron Ka Katerenc nchuk huk Aaron is a professional engineer holding a BSc Engineering from the University of Alberta, Canada. Aaron has 11 years experience in oil & gas specializing in project management with recent focus in acquisitions and dispositions (closing and integrating $100+ million- dollars in transactions). More recently Aaron held a position with Vibe Bioscience as Vice President of Business Development, facilitated in the process of taking Vibe public in Spring 2019 listing on the Canadian Securities Exchange. Aaron’s core focus at Vibe was product development (THC and CBD concentrates), retail, cultivation and evaluating acquisition opportunities. He has spent four years directly involved in the cannabis space with investment in cultivation, US retail and e-commerce companies both private and public.

F e b r u a r y 2 0 2 0

• CANNSUN-MEDHEL

27

23

Ar Arte temios Ch Charalampaki kis Artemios was born in Athens Greece. He is a graduate of the Department of Earth Sciences at the University of Athens, and has an MBA from the University of Leicester with specialization in International Marketing. He has served as senior manager and as an executive with several multinational and Greek companies, such as S&V Technologies GmbH, TAD Pharma GmbH, AstraZeneca, Abbott Laboratories, ALAPIS group of companies etc. Artemios has 20 years of experience as commercial development and management in pharmaceutical, food supplements and cosmetics industries. Artemios holds the position of the Chief Commercial Officer. Ma Manos Angelakis Manos was born in Athens Greece. A graduate of the Department of Physiotherapy in the University of Athens, he also holds a Bachelor in Business Administration from London Metropolitan University. Manos has worked for several pharmaceutical and cosmetics multinational companies as a senior manager. He also has extensive experience for over 20 years as General Manager for several companies in the Risk Management sector (Patriot Group of Companies) which was on of the biggest companies in maritime security worldwide. Manos is the main shareholder of two companies active in Risk Management (Vanguard-Risk- group) & Geostationary Satellites (Cosmos-satellites). Manos holds the position of the CEO in Cannsun-Medhel Commercial. Ma Manoli Ka Kaldi dis Emmanouil has over 20 years of experience as an architect and has also been involved in advertising, industrial design and

• tourism. Some of his biggest clients have included Coca Cola, Philp Morris, Nike and Harley Davidson.

Manolis is the secretary of the Union of Small Hotels in Sithonia, Halkidiki and representative of the Halkidiki Tourism Federation. He is characterized by his multitasking skills complemented with his ability to speak both Greek and English.

LEADERSHIP BACKGROUND

F e b r u a r y 2 0 2 0

• CANNSUN-MEDHEL

28

23

LEADERSHIP BACKGROUND

Le Leondios Caldis Leondios completed his undergraduate studies in 2013, being awarded a Bachelor of Business Administration and a Diploma in International Marketing (IMM Graduate School of Marketing). In that same year, Leon ventured a start-up in the credit loan sector, partnering with African Bank. Leondios is responsible for driving Cannsun’s sales and leading the company’s marketing presence in the medical cannabis industry in South Africa. He is also heavily involved in the daily operations of the company. Don Donaghue Wood

• odman

Donaghue’s role relates to regulatory aspects of the business, as well as new product and portfolio development, new business and strategic research development. She holds an MBA with a background in biochemistry and pharmacology (focusing on active molecules in natural medicines) with the South African Herbal Medicine and Science Institute. She has nine years of sales and marketing experience within the pharmaceutical industry, in both the public and private sector, across a broad range of therapeutic areas including Woman’s health, CNS, Respiratory, Gastroenterology, Anaesthesiology, dermatology, Cystic Fibrosis, Pancreatic Cancer and

• Pain. Her passion is philanthropy, people and business, and she is a keynote motivational speaker for the Global Business Roundtable.

Gr Greg eg Bealer ealer Greg obtained his Bachelor of Commerce degree majoring in Business Law and Economics from the University of Alberta, Canada. Greg recently retired after 11 years as an Investment Advisor and Portfolio Manager. He turned his core focus on the pharmaceutical and cannabis industry in 2013. Greg has been actively involved in financing of Canadian and international cannabis startups and brings both experience and knowledge of the capital markets.

F e b r u a r y 2 0 2 0

• CANNSUN-MEDHEL

29

23

LEADERSHIP BACKGROUND

Ch Chris s Br Brockl klesb sby Chris is a CPA-CA currently holding the position of CFO for the Houwelings Group. He has also held roles with KPMG and Village Farms International Inc. where he gained expertise in US/Canada taxation, finance and operation. Chris has raised and restructured over $100m in senior and subordinate debt-related projects in Canada and the US. He is also responsible for intellectual property management, lender relationships and all legal matters. He is accountable for the Finance, Legal, IT, Risk Management, Food and Health Compliance and HR departments for the Group of Companies. He holds a B.Sc. in Agroecology and a Diploma in Accounting from UBC. Pe Peter Cummings gs Peter currently provides financial advisory services to Agricultural Enterprises in the Horticultural and Insect Farming Sectors. Before engaging in private consultancy, Peter was the CFO for the Houwelings Group from 2003 to 2012, and the CFO for BC Hot House Foods from 1997 to 2003. Peter has had senior management roles with Shoppers Drug Mart between 1984 and

• 1997. He obtained his CA designation in 1982 and obtained a Bachelor of Commerce from UBC in 1978.

Va Vassilis Di Dimou

• u

After his academic studies majoring in economics at the University of Siegen and Köln, Vassilis worked in various management positions in the area of syndication and investment and corporate banking with the strong focus on structured and international projects – Export Credit Agency (ECA) and Finance in the RES and Retrofit Finance area. Vassilis has long standing contracts to the finance executives and government, with a focus on the Greek regional economy to establish a Local (Public) Banking System for the local Greek SME Sector and the local population across the country, bridging public sector institutions and private

F e b r u a r y 2 0 2 0

• CANNSUN-MEDHEL

30

23

LEADERSHIP BACKGROUND

Ev Evdo dokia Ka Karagouni uni Research Director & Member of the HPI Scientific Council. He is Head of the Microbiology Department, Group leader of the Parasite Immunology & Vaccine Development at the Laboratory of Cellular Immunology, Hellenic Pasteur Institute. Evdokia obtained her BSc in Biology at the Aristotle University of Thessaloniki in 1982, and her PhD in Immunobiology at the same University in 1989, and carried

• ut a four year post-doctoral training at the Department of Parasitology, Evdokia joined the Laboratory of Cellular Immunology at the

Hellenic Pasteur Institute (1994) as an assistant researcher, where since 2014, she held the position of the Research Director. She has published 70 original papers in peer-reviewed journals Bh Bhunya yanee De Dethamart Bhunyanee is a Thailand-based Chemist who has built a career working for Thailand and Italian based companies. The previous 17 years she has been with Eagle Chemical IND. of Thailand and Alpa SPA of Italy in roles from Research and Development Officer, Sales and Chief Operating Officer. In her role at Cannsun Medhel Group, Bhunyanee will directly support both the CEO and COO. She is a graduate

• f Sukhothai Thamathirat (Technology) University in 2002. Over the past several years, Bhunyanee has been in the Cannabis space

making Bespoke cosmetics and natural medicine. She has been key figure in the project development in Asia.

F e b r u a r y 2 0 2 0

• CANNSUN-MEDHEL

31

CORPORATE STRUCTURE

Cannsun IP-R&D Ireland Cannsun Medhel Group PLC Ireland Cannsun Medhel Commercial Greece Medhel Greece Agraleaf Greece Cannsun South Africa Cannsun Lesotho Mohlodi Lesotho Cannsun Europe Germany Cannsun Medhel China

F e b r u a r y 2 0 2 0

• CANNSUN-MEDHEL

32

REVENUE PROFILE BREAKDOWN

S a l e s R e v e n u e s ( € M ) 2 0 2 0 2 0 2 1 2 0 2 2 P h a r m a c e u t i c a l s G r e e c e 8 , 2 2 2 4 9 , 4 7 7 5 8 , 3 9 3 F S M P s G r e e c e 2 , 0 2 6 8 , 3 2 4 1 4 , 9 8 0 O T C / C o s m e t i c s G r e e c e 2 , 5 2 7 4 , 3 1 6 7 , 3 3 7 E x p o r t s 6 3 0 1 , 4 1 0 2 , 0 3 2 J V S a l e s 1 , 1 0 0 2 , 7 0 0 4 , 3 0 0 S e l e c t i v e C h a n n e l s 5 , 7 7 2 1 2 , 0 5 6 1 6 , 1 3 1 C B D P r o d u c t s 3 , 1 2 3 1 0 , 6 5 1 1 9 , 5 5 0 T H C P r o d u c t s 4 , 0 0 0 8 , 0 0 0 C o n t r a c t e d R e v e n u e s 7 , 6 0 0 8 , 4 0 0 8 , 4 0 0 G R A N D T O T A L 3 1 , 0 0 0 1 0 1 , 3 3 5 1 3 9 , 1 2 4

F e b r u a r y 2 0 2 0

• CANNSUN-MEDHEL

33

1

Description

• Est. Cost (€ )

1. 5000 m² New Production Plant (Cytotoxic & Injectables) 9,000,000 2. 3,000 m² New Building Warehouse 2,000,000 3. Factory Renovation 6,000,000 4. Office & Basement Space Reconstruction 1,300,000 5. Security Fences, Surveillance System, Access Control 900,000 6. Industrial modifications of surrounding Area 500,000 7. New Building, educational training center, retail store 2,500,000 8. 40,000 m² Land Purchase 600,000

2 3 4 5 6 7 8

Loan A (3,4,5) 6,970,000 Loan B (2,6,7) 4,250,000 Loan C (1) 7,650,000 Equity 3,930,000 Total Investment (€) 22,800,000

MEDHEL FACILITY EXPANSION (3 YEARS)

Debt Financing level 85% Potential EU government grant of € 7.0 MM upon successful qualification

F e b r u a r y 2 0 2 0

• CANNSUN-MEDHEL

34

DISCLAIMER

This presentation is very forward-looking in its statements, and these statements may not be based on fact, including without limitation, statements regarding Cannsun Medhel’s (“Cannsun”) expectations in respect of its ability to successfully execute its business plan; its ability to raise additional capital and fund its ongoing operations; plans for future growth and the direction of the business; financial projections including expected revenues, gross profits, and EBITDA (which is anon-GAAP financial measure); plans to increase product volumes, the capacity of existing facilities, supplies from third party contractors; expected growth of the cannabis industry generally; management’s expectations, beliefs and assumptions; events or developments that Cannsun expects to take place in the future; and general economic conditions. All statements, other than statements of historical facts, are forward-looking information and statements. The words “believe”, “expect”, “anticipate”, “contemplate”, “target”, “intends”, “continue”, “budget”, “estimate”, “may”, “will”, and similar expressions identify forward-looking information and statements. Such forward-looking information and statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Cannsun as of the date of such information and statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Known and unknown factors could cause actual results to differ materially from those projected in the forward-looking information and statements. Such factors include, but are not limited to, the inability of Cannsun to generate sufficient revenues or raise sufficient funds to carry out its business plan; changes in government legislation, taxation, controls, regulations and political or economic developments in various countries; risks associated with agriculture and cultivation activities generally, Including inclement weather, access to supply of seeds, poor crop yields, and spoilage; compliance with import and export laws of various countries; significant fluctuations in cannabis prices and transportation costs; the risk

• f obtaining necessary licenses and permits; inability to identify, negotiate and complete a potential acquisition for any reason; the ability to retain key employees; dependence
• n third parties for services and supplies; non-performance by contractual counterparties; general economic conditions; and the continued growth in global demand for

cannabis products and the continued increase in jurisdictions legalizing cannabis; and the timely receipt of regulatory approval for Cannsun’s license applications. The foregoing list is not exhaustive and Cannsun undertakes no obligation to update any of the foregoing except as required by law. Many of these uncertainties and contingencies could affect Cannsun’s actual performance and cause its actual performance to differ materially from what has been expressed or implied in any forward-looking information and statements made by, or on behalf of, Cannsun. Readers are cautioned that forward-looking information and statements are not guarantees of future performance. There can be no assurance that such information and statements will prove to be accurate and actual results and future events could differ materially from those acknowledged in such information and statements. CANNSUN disclaims any intention or obligation to update or revise any forward-looking information and statements whether as a result of new information, future events or

• therwise, except to the extent required by applicable laws.

20